药物治疗方案复杂性和多重用药作为老年人全因死亡率相关因素:一项基于人群的队列研究。

Medication Regimen Complexity and Polypharmacy as Factors Associated With All-Cause Mortality in Older People: A Population-Based Cohort Study.

作者信息

Wimmer Barbara C, Bell J Simon, Fastbom Johan, Wiese Michael D, Johnell Kristina

机构信息

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

出版信息

Ann Pharmacother. 2016 Feb;50(2):89-95. doi: 10.1177/1060028015621071. Epub 2015 Dec 17.

Abstract

OBJECTIVES

To investigate whether medication regimen complexity and/or polypharmacy are associated with all-cause mortality in older people.

METHODS

This was a population-based cohort study among community-dwelling and institutionalized people ≥60 years old (n = 3348). Medication regimen complexity was assessed using the 65-item Medication Regimen Complexity Index (MRCI) in 10-unit steps. Polypharmacy was assessed as a continuous variable (number of medications). Mortality data were obtained from the Swedish National Cause of Death Register. Cox proportional hazard models were used to compute unadjusted and adjusted hazard ratios (HRs) and 95% CIs for the association between regimen complexity and polypharmacy with all-cause mortality over a 3-year period. Subanalyses were performed stratifying by age (≤80 and>80 years), sex, and cognition (Mini-Mental State Examination [MMSE] <26 and ≥26).

RESULTS

During follow-up, 14% of the participants (n = 470) died. After adjusting for age, sex, comorbidity, educational level, activities of daily living, MMSE, and residential setting, a higher MRCI was associated with mortality (adjusted HR = 1.12; 95% CI = 1.01-1.25). Polypharmacy was not associated with mortality (adjusted HR = 1.03; 95% CI = 0.99-1.06). When stratifying by sex, both MRCI and polypharmacy were associated with mortality in men but not in women. MRCI was associated with mortality in participants ≤80 years old and in participants with MMSE ≥26 but not in participants >80 years old or with MMSE <26.

CONCLUSION

Regimen complexity was a better overall predictor of mortality than polypharmacy. However, regimen complexity was not predictive of mortality in women, in participants >80 years old, or in those with MMSE<26. These different associations with mortality deserve further investigation.

摘要

目的

调查用药方案复杂性和/或多种药物联合使用是否与老年人全因死亡率相关。

方法

这是一项基于人群的队列研究,研究对象为60岁及以上的社区居民和机构养老人员(n = 3348)。用药方案复杂性采用65项用药方案复杂性指数(MRCI)以10为单位进行评估。多种药物联合使用作为连续变量(药物数量)进行评估。死亡率数据来自瑞典国家死亡原因登记处。采用Cox比例风险模型计算3年期间用药方案复杂性和多种药物联合使用与全因死亡率之间关联的未调整和调整风险比(HR)及95%置信区间(CI)。按年龄(≤80岁和>80岁)、性别和认知功能(简易精神状态检查表[MMSE]<26分和≥26分)进行亚组分析。

结果

随访期间,14%的参与者(n = 470)死亡。在调整年龄、性别、合并症、教育水平、日常生活活动能力、MMSE和居住环境后,较高的MRCI与死亡率相关(调整后HR = 1.12;95%CI = 1.01 - 1.25)。多种药物联合使用与死亡率无关(调整后HR = 1.03;95%CI = 0.99 - 1.06)。按性别分层时,MRCI和多种药物联合使用均与男性死亡率相关,但与女性死亡率无关。MRCI与≤80岁的参与者以及MMSE≥26分的参与者的死亡率相关,但与>80岁的参与者或MMSE<26分的参与者的死亡率无关。

结论

与多种药物联合使用相比,用药方案复杂性是更好的全因死亡率总体预测指标。然而,用药方案复杂性并不能预测女性、>80岁的参与者或MMSE<26分的参与者的死亡率。这些与死亡率的不同关联值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba19/4714103/798b457923e4/10.1177_1060028015621071-fig1.jpg

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索